Eisai, one of the world's leading research and development, focusing on pharmaceutical companies, has received approval for its Fycompa, an antiepileptic drug (perampaneeli) to replace the basic medicine in Finland. Perampaneeli is intended onset, secondary generalization in seizures in the adjuvant at least 12 years of age in patients with epilepsy.

Perampaneeli is the first and only authorized in anti-epileptic drug that acts selectively on AMPA receptors, which have a decisive influence on the formation of seizures. This mechanism of action differs from other, currently available anti-epileptic drugs. Perampaneeli administered once a day at bedtime, and it is noteworthy that it is the only activity in the treatment of epilepsy referred to a new generation drug that is already approved for use in sales usher in young patients with epilepsy from the age of 12.

"Perampaneeli is an important new treatment option for partial-onset seizures for people with Finnish patients, especially those with seizures are uncontrollable," says associate professor Jukka Peltola (Tampere University Hospital, Neuroalat and rehabilitation). "Treatment of epilepsy can be challenging, so doctors across the country are certainly happy to get perampaneelista option, which can help patients with epilepsy to improve the management of seizures."

Epilepsy is one of the most common neurological diseases, affecting Finland, about 56 000 people. Although anti-epileptic drugs, there are plenty, effective treatment of partial seizures in some patients, is still very challenging. At present, 20-40 per cent of patients who have recently received a diagnosis of epilepsy, poorly responsive to treatment.

The European Commission adopted on 23 perampaneelin July 2012 based on three randomized, double-blind, placebo-controlled and carried out in an ascending dose, phase III study (304, 305, 306) and open label extension study (307). These three pivotal studies showed consistent results perampaneelin the effectiveness and tolerability of onset, secondarily generalization of seizures in the adjuvant setting. The most commonly reported adverse events were dizziness, somnolence, fatigue, headache, falls, irritability and ataxia, open-label extension study indicate perampaneelin effectiveness and good tolerability in the long term.

Eisai AB, the Nordic Council of Medical Director Sten Friberg, says: "We are delighted to announce the results Fycompan sale in Finland. Eisai epilepsy industry leader will arise, and we are committed to developing this kind of innovative treatments to help epilepsy patients may improve seizure control."

Perampaneelin introduction of the Finnish market reflects Eisai's human health care mission (human health care mission), which is the company's goal of providing innovative solutions for disease prevention, healing and treatments and to promote the well-being around the world.

Perampaneeli has been approved in the European Union as adjunctive, secondary generalization in epileptic seizures for at least 12 years of age in patients with epilepsy. Perampaneeli is a highly selective, noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoksatsoliproprionihapon (AMPA) glutamate receptor antagonist, which is 2 and 3 phase II trials been shown to reduce seizures. AMPA receptors are found in abundance in almost all excitatory neurons. They transmit signals, which stimulates the nerve cells in the brain excitatory neurotransmitter glutamate, and is believed to be involved in CNS disorders such as epilepsy, which are characterized by neuronal ylieksitaatio.

Eisai is committed to develop and make available effective new treatments to help sufferers of epilepsy. Epilepsy Eisai Pharmaceutical development is a major strategic area of operation in EMEA (Europe, Middle East, Asia).